- @immpressmag #Innovation and #Commercialization, where we discuss the process… https://t.co/Kk3JKvRYpe@immpressmag @DarioInScience: Anifrolimumab (Anti-IFNAR Therapy) meets endpoint in phase III clinical trial - a big step forward for biologic therapy…@immpressmag https://t.co/vqUC138bR8@immpressmag #IMMpressMagazine talks drug use and addiction, challenging conventional ideas… https://t.co/iQ6oJ7eEN2
IMMpress Magazine is generously supported by BioLegend and the University of Toronto. Read More about “Sponsors”…
Want the scoop on immunology and graduate education? Subscribe to IMMpress Magazine for all the latest updates.
IMMpress Magazine is proudly affiliated with Science Borealis and BenchSci. Check out their websites for more great reading on science, research and graduate life.